Dr. Sanft on Sequencing of Treatments for HER2+ Breast Cancer

Tara Sanft, MD
Published: Thursday, Feb 02, 2017



Tara Sanft, MD, assistant professor of Medicine, medical director of Adult Survivorship for Yale Cancer Center Survivorship Clinic, discusses sequencing of treatments for patients with HER2-positive breast cancer.

The combination of trastuzumab (Herceptin) and pertuzumab (Perjeta) is typically what patients will start with, explains Sanft. It usually begins with combination chemotherapy and over time as the disease becomes more controlled, you can eliminate the chemotherapy if toxicities arise, and continue on with trastuzumab or pertuzumab alone.

Patients who were previously metastatic can have long-term disease-control with essentially no evidence of disease. If the cancer continues to grow the patient can switch to trastuzumab emtansine (TDM-1), which has also been shown to be effective in patients with HER2-positive breast cancer.
 


Tara Sanft, MD, assistant professor of Medicine, medical director of Adult Survivorship for Yale Cancer Center Survivorship Clinic, discusses sequencing of treatments for patients with HER2-positive breast cancer.

The combination of trastuzumab (Herceptin) and pertuzumab (Perjeta) is typically what patients will start with, explains Sanft. It usually begins with combination chemotherapy and over time as the disease becomes more controlled, you can eliminate the chemotherapy if toxicities arise, and continue on with trastuzumab or pertuzumab alone.

Patients who were previously metastatic can have long-term disease-control with essentially no evidence of disease. If the cancer continues to grow the patient can switch to trastuzumab emtansine (TDM-1), which has also been shown to be effective in patients with HER2-positive breast cancer.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Publication Bottom Border
Border Publication
x